Vnitr Lek 2013, 59(9):769-775

Use of natriuretic peptides in diagnosis of left ventricular hypertrophy in obese hypertensive patients with metabolic syndrome

J. Špác1,*, M. Beránek2, H. Němcová1, B. Kianička1, M. Souček1
1 II. interní klinika Lékařské fakulty MU a FN u sv. Anny Brno, přednosta prof. MUDr. Miroslav Souček, CSc.
2 Data Marketing Management s.r.o., Brno, ředitel RNDr. Michal Beránek

Introduction:
Presence of left ventricular (LV) hypertrophy significantly increases cardiovascular risk in patients suffering from hypertension. Diagnostics of LV hypertrophy in hypertensive patients is not easy and there is still no method of enabling a simple and sufficiently sensitive diagnosis across a large patient population. The golden standard in LV hypertrophy diagnostics is echocardiography, and there are adverse opinions regarding the use of natriuretic peptides BNP and NT-proBNP (NP) to diagnose LV hypertrophy.

Patients and methods:
We examined through echocardiography 173 hypertensive patients with signs of metabolic syndrome and a moderate increase in blood pressure (130-159/85-99 mm Hg) with an average age of 54.8 ± 13.54 years, i.e. 119 men and 54 women, who were divided into 2 groups; 1 with BMI > 30 (group A with a severe obesity) and the other without obesity, BMI < 30 (group B). Both groups were examined for BNP and NT-proBNP levels.

Results:
We found a positive correlation between NP and LVMi, both for BNP (r = 0.169; p = 0.033) and for NT-proBNP (r = 0.240; p = 0.002). NT-proBNP statistically significantly predicts the given LV hypertrophy LK in people with BMI < 30 but not in obese people (BMI > 30).

Conclusion:
Obese patients suffer from a higher occurrence of left ventricular hypertrophy and paradoxically a lower NP value than patients with a metabolic syndrome (MS) who are not obese. Natriuretic peptides have a limited diagnostic value when assessing left ventricular hypertrophy. They are only of value in patients who are not obese and whose kidney function and systolic myocardial function have not been impaired.

Keywords: left ventricular hypertrophy; metabolic syndrome

Received: October 29, 2012; Accepted: April 3, 2013; Published: September 1, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Špác J, Beránek M, Němcová H, Kianička B, Souček M. Use of natriuretic peptides in diagnosis of left ventricular hypertrophy in obese hypertensive patients with metabolic syndrome. Vnitr Lek. 2013;59(9):769-775.
Download citation

References

  1. Nishikimi T, Yoshihara F, Morimoto A et al. Relationship between left ventricular geometry and natriuretic peptide levels in essential hypertension. Hypertension 1996; 28: 22-30. Go to original source... Go to PubMed...
  2. Jakubík P, Janota T, Wichterle D et al. Může závažná esenciální hypertenze způsobit vzestup BNP vedoucí k falešné diagnóze srdečního selhání? Cor Vasa 2006; 48: 48-54. Go to original source...
  3. Gardner DG, Chen S, Glenn DJ et al. Molecular Biology of Natriuretic Peptide System. Hypertension 2007; 49: 419-426. Go to original source... Go to PubMed...
  4. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-3421. Go to original source...
  5. Sahn DJ, DeMaria A, Kisslo J et al. The committee on Mode Standardization of the American Society of Echocardiography: recommendations regarding quantification in Mode echocardiography: results of a survey of echocardiographic methods. Circulation 1978; 58: 1072-1083. Go to original source... Go to PubMed...
  6. de Simone G, Daniels SR, Devereux RB et al. Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and impact of overweight. J Am Coll Cardiol 1992; 20: 1251-1260. Go to original source... Go to PubMed...
  7. Hildebrandt P, Boesen M, Olsen M et al. N-terminal pro brain natriuretic peptide in arterial hypertension - a marker for left ventricular dimensions and prognosis. Eur J Heart Fail 2004; 6: 313-317. Go to original source... Go to PubMed...
  8. Muller-Brunotte R, Kahana T, Lopez B et al. Myocardial fibrosis and diastolic dysfunction in patients with hypertension: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVIA). J Hypertens 2007; 25: 1958-1966. Go to original source... Go to PubMed...
  9. Almeida P, Azevedo A, Rodrigues R et al. B type natriuretic peptide and left ventricular hypertrophy in hypertensive patients. Rev Port Variol 2003; 22: 327-336.
  10. Gomes AH, Morillas P, Quiles J et al. Diagnostic accuracy of NT pro BNP compared with the electrocardiogram in detecting left ventricular hypertrophy of hypertensive origin. ESC Congress, Paris 2011.
  11. Lopez B, González A, Lasarte JJ et al. Is plasma cardiotrophin-1 a marker of hypertensive heart disease? J Hypertens 2005; 23: 625-632. Go to original source... Go to PubMed...
  12. Olsen MH, Hansen TW, Christensen MK et al. N-terminal pro brain natriuretic peptide is inversely related to metabolic cardiovascular risk factors and the metabolic syndrome. Hypertension 2005; 46: 660-666. Go to original source... Go to PubMed...
  13. Kälsch H, Neumann T, Erbel R. Less increase of BNP and NT pro BNP levels in obese patient with decompensated heart failure: interpretation of natriuretic peptides in obesity. Int J Cardiol 2009; 133: e22-e24. Go to original source... Go to PubMed...
  14. Krauser DG, Lloyd-Jones DM, Chae CU et al. Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure. A ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudy. Am Heart J 2005; 149: 744-750. Go to original source... Go to PubMed...
  15. Davis ME, Richards AM, Nicholls MG et al. Introduction of metoprolol increases plasma B-type cardiac natriuretic peptides in mild, stable heart failure. Circulation 2006; 113: 977-985. Go to original source... Go to PubMed...
  16. de Simone G, Muiesan ML, Ganau A et al. Reliability and limitations of echocardiographic measurement of left mass for risk stratification and follow-up in single patients. The RES trial. Working group on Heart and Hypertension of the Italian Society of Hypertension. Reliability of M-mode Echocardiographic Studies. J Hypertens 1999; 17: 1955-1963. Go to original source... Go to PubMed...
  17. de Simone G, Daniels SR, Devereux RB et al. Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and impact of overweight. J Am Coll Cardiol 1992; 20: 1251-1260. Go to original source... Go to PubMed...
  18. Frohlich ED, Gonzalez A, Díez J. Hypertensive left ventricular hypertrophy risk: beyond adaptive cardiomyocytic hypertrophy. J Hypertens 2011; 29: 17-26. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.